Shimadzu saw the highest growth of 1.29% in patent filings and 1.12% in grants in May in Q2 2024. Compared to Q1 2024, Q2 2024 saw an increase in patent filings by 0.82% and grants by 0.95%. GlobalData’s DataBook provides a comprehensive analysis of Shimadzu‘s patent filings and grants. Buy the databook here.
Shimadzu has been focused on protecting inventions in Japan(JP) with 136 publications in Q2 2024
The Japan(JP) Patent Office dominates the patent filings and grants with nearly 21% filings and 44% grants. The China(CN), United States(US), Japan(JP), and World Intellectual Property Organization(WIPO) patent Office are among the top ten patent offices where Shimadzu is filings its patents. Among the top granted patent authorities, Shimadzu has 44% of its grants in Japan(JP), 27% in China(CN) and 26% in United States(US).
Thermo Fisher Scientific and Regeneron Pharmaceuticals could be the strongest competitors for Shimadzu
Patents related to industrial automation and healthtech lead Shimadzu's portfolio
Shimadzu has the highest number of patents in industrial automation followed by, healthtech and robotics. For industrial automation, nearly 55% of patents were filed and 49% of patents were granted in Q2 2024.
Image management related patents lead Shimadzu portfolio followed by diagnostic imaging, and consumer applications
Shimadzu has highest number of patents in image management followed by diagnostic imaging, consumer applications, healthcare it, and other remote patient monitoring. For image management, nearly 22% of patents were filed and 19% of patents were granted in Q2 2024.
For comprehensive analysis of Shimadzu's filings and grants, buy the databook here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.